Evaluation of serial creatinine measurements with reference change value in gentamicin-treated patients: a new tool in nephrology practice?

Basit Öğe Kaydı
dc.authorid0000-0001-5667-1805
dc.authorid0000-0003-1944-2477
dc.authorid0000-0002-4082-6320
dc.authorid0000-0002-7161-2907
dc.contributor.authorYavuz, Demet
dc.contributor.authorCinpolat, Havva Yasemin
dc.contributor.authorKal, Oznur
dc.contributor.authorErdem, Mukadder
dc.contributor.authorAlkan, Sevil
dc.contributor.authorDemirag, Mehmet Derya
dc.contributor.authorAydemir, Nihal
dc.date.accessioned2026-02-03T12:02:21Z
dc.date.available2026-02-03T12:02:21Z
dc.date.issued2025
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractIntroduction In this study, we aimed to evaluate serum creatinine levels with reference change value in patients receiving treatment with gentamicin. Methods Serum creatinine levels of patients who received gentamicin were recorded retrospectively before treatment and on the 7th and 14th days after treatment. Analytical coefficient of variation (s/x) x 100 (CV) and reference change value were calculated (z = 1.64,; P < .05). The percentage increase in serum creatinine level at day 7 and day 14 compared with before treatment was considered statistically significant if it exceeded the reference change value. Nephrotoxicity was assessed by comparing changes in serum creatinine levels using reference change value and Kidney Disease: Improving Global Outcomes (KDIGO) criteria. Results A total of 55 patients with a mean (SD) age of 53 (17) years were included in the study. The reference change value for serum creatinine was calculated as11.9%. The rate of increase in serum creatinine levels showed a statistically significant increase in 45.5% and 63.6% of patients on days 7 and 14, respectively, compared with before treatment, while the increase was statistically significant in 8.2% and 25.5% of patients, respectively, when evaluated by KDIGO criteria. Discussion We believe that it would be in the patient's best interest for clinicians to include reference change value in clinical nephrology practice alongside known acute kidney failure criteria.
dc.identifier.doi10.1093/labmed/lmaf076
dc.identifier.issn0007-5027
dc.identifier.issn1943-7730
dc.identifier.pmid41236859
dc.identifier.urihttps://doi.org/10.1093/labmed/lmaf076
dc.identifier.urihttps://hdl.handle.net/20.500.12428/34704
dc.identifier.wosWOS:001616243200001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherOxford Univ Press
dc.relation.ispartofLaboratory Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20260130
dc.subjectgentamicin
dc.subjectreference change value
dc.subjectacute kidney injury
dc.subjectserial creatinine measurements
dc.subjectnephrotoxicity
dc.subjectacute kidney failure criteria
dc.titleEvaluation of serial creatinine measurements with reference change value in gentamicin-treated patients: a new tool in nephrology practice?
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu